Posted January 26, 2018

Seller of Coenzyme-A Warned For Making Drug Claims

On January 5, 2018, the FDA issued a warning letter to Coenzyme A, Inc. following a facility inspection and review of the company's website that found the company made drug claims about its product Coenzyme-A.

These claims include: 
  • "Coenzyme-A initiates the fatty acid metabolism . . . essential to the avoidance of the high levels of cholesterol and triglycerides, and the high lipid levels that are characteristic of patients with cardiovascular or diabetic disorders."

  • "What are the symptoms of a deficiency of Coenzyme-A? . . . depression, anxiety . . . frequent respiratory infection, cardiac instability, and abnormal need for sleep. Neurological disorders included: numbness, muscle weakness, cramps, abdominal pain and paresthesia (abnormal sensations such as itching and prickling, tingling extremities, and "burning feet" syndrome). Biochemical changes included: . . . lowered blood cholesterol . . . and failure of adrenocorticotropin (ACTH) to induce eosinopenia."

  • "The diseases of age that usually cause disability or death such as arthritis, multiple sclerosis, parkinson's, alzheimer's, adult on-set diabetes, cancer, artherosclerosis, etc. are usually prevented or alleviated by a well-functioning immune system and healthy DNA. As noted above, Coenzyme-A . . . facilitates the repair of RNA and DNA."

  • " . . . (Coenzyme-A) plays a major role in the body's ability to cope with . . . anxiety, and depression . . . ."

  • "Coenzyme-A has been medically applied as a dietary supplement for . . . such very serious diseases as Diabetes, Obesity and Heart failure." 

See related warnings:

Seller of CoQ10, Anxiety Supplements and More Warned for Manufacturing Violations, Drug Claims

Life Extension Warned For Drug Claims

Seller of BrainAlert Warned for Manufacturing Violations, Drug Claims

To see the full FDA Warning Letter follow the link below.